# A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

> **NCT05093933** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6106 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Vericiguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05093933
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-02
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-02-05
- **Target enrollment:** 6106 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093933, "A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05093933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*